These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 15275708)

  • 1. How and why does radioimmunotherapy work?
    Macklis RM
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1269-71. PubMed ID: 15275708
    [No Abstract]   [Full Text] [Related]  

  • 2. [Radioimmunotherapy in non-Hodgkin's lymphoma. With focus on anti-CD20 treatment].
    de Nully Brown P; Jurlander J; Lindén O; Hansen M
    Ugeskr Laeger; 2005 Oct; 167(41):3867-9. PubMed ID: 16221425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Radioimmunotherapy for B-cell lymphoma].
    Tobinai K
    Rinsho Ketsueki; 2006 Jun; 47(6):463-70. PubMed ID: 16862974
    [No Abstract]   [Full Text] [Related]  

  • 4. [Radioimmunotherapy with (90)Y-Ibritumomab tiuxetan].
    Brockmann H; Biersack HJ
    Dtsch Med Wochenschr; 2006 Mar; 131(9):438-40. PubMed ID: 16493567
    [No Abstract]   [Full Text] [Related]  

  • 5. Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphoma.
    Hernandez MC; Knox SJ
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1274-87. PubMed ID: 15275710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Some like it hot!
    Cheson BD
    J Clin Oncol; 2001 Oct; 19(19):3908-11. PubMed ID: 11579110
    [No Abstract]   [Full Text] [Related]  

  • 7. [Targeted destruction of lymphomas with the aid of radioimmunotherapy. Tumor antibodies isotope taxi].
    MMW Fortschr Med; 2004 Apr; 146(15):66. PubMed ID: 15373026
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma.
    Meredith RF; Knox SJ
    Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S15-22. PubMed ID: 16979433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioimmunotherapy: a new treatment modality for B-cell non-Hodgkin's lymphoma.
    Ghobrial I; Witzig T
    Oncology (Williston Park); 2004 May; 18(5):623-30; discussion 633-4, 637-8, 640. PubMed ID: 15209190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioimmunotherapy for B-cell non-Hodgkin lymphoma.
    Witzig TE
    Best Pract Res Clin Haematol; 2006; 19(4):655-68. PubMed ID: 16997175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioimmunotherapy of non-Hodgkin's lymphoma revisited.
    Goldenberg DM; Sharkey RM
    J Nucl Med; 2005 Feb; 46(2):383-4. PubMed ID: 15695801
    [No Abstract]   [Full Text] [Related]  

  • 12. Radioimmunotherapy with (90)Y-ibritumomab tiuxetan is a safe and efficient treatment for patients with B-cell lymphoma relapsed after auto-SCT: an analysis of the international RIT-Network.
    Hohloch K; Zinzani PL; Linkesch W; Jurczak W; Deptala A; Lorsbach M; Windemuth-Kiesselbach C; Wulf GG; Truemper LH
    Bone Marrow Transplant; 2011 Jun; 46(6):901-3. PubMed ID: 20871640
    [No Abstract]   [Full Text] [Related]  

  • 13. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
    Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
    J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioimmunotherapy with (131)I-rituximab for patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL).
    Kang HJ; Lee SS; Kim KM; Choi TH; Cheon GJ; Kim WS; Suh C; Yang SH; Lim SM
    Asia Pac J Clin Oncol; 2011 Jun; 7(2):136-45. PubMed ID: 21585693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan.
    Witzig TE; Molina A; Gordon LI; Emmanouilides C; Schilder RJ; Flinn IW; Darif M; Macklis R; Vo K; Wiseman GA
    Cancer; 2007 May; 109(9):1804-10. PubMed ID: 17380530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Nuclear medicine and lymphoma].
    Fernández de Sevilla Ribosa A
    Rev Esp Med Nucl; 2006; 25(2):77-9. PubMed ID: 16759612
    [No Abstract]   [Full Text] [Related]  

  • 17. [New trends in non-Hodgkin's lymphoma therapy].
    Mazur G; Wróbel T; Jurczak W; Butrym A
    Postepy Hig Med Dosw (Online); 2006; 60():707-21. PubMed ID: 17245320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
    J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioimmunotherapy of Non-Hodgkin's lymphoma.
    Britton KE
    J Nucl Med; 2004 May; 45(5):924-5. PubMed ID: 15136647
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeted treatment for non-Hodgkin's lymphoma.
    Health News; 2002 May; 8(5):7. PubMed ID: 12132412
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.